THC Biomed Intl EBIT

The latest EBIT for THC.CN is $-3M as of April 2023. That compares with $-2.6M in the prior-year period — down 17.5% year over year. That is above the sector sector average of $-25M. Investors often review this figure alongside THC Biomed Intl's historical trend and sector peers before judging valuation or financial health.

Over the past year, THC.CN's EBIT moved from $-2.6M to $-3M — a 17.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in THC Biomed Intl's operating scale or balance-sheet position.

Against its sector companies, THC.CN currently prints $-3M for EBIT, while the sector average sits near $-25M. That is roughly 88.0% above the sector mean. Large gaps often invite a closer look at THC Biomed Intl's growth, margins, and balance sheet.

A EBIT figure of $-3M for THC.CN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-25M. Explore the charts below for those layers of context.

After noting THC.CN's EBIT ($-3M), review year-over-year change from $-2.6M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.